To: Edscharp who wrote (16868 ) 5/21/2004 12:20:39 AM From: Bluegreen Read Replies (1) | Respond to Ed, it is simply a Matrix of Metrics. Do you see where the elements of ALL the trials of Raptiva might be the coefficients of a classical SUBSET chi-square matrix? For example, they have ALL kinds of therapies across the pond for UNCONTROLLED proliferation of skin cells aka PSORIASIS!!!! In SOME people the therapies have FAILED hence the grand entrance of RAPTIVA. How did RAPTIVA perform???? Can you say SMARTYRAPTIVA???? BTW it is a FIRST AND don't you just LOVE all those zeros after the little p????? AND the N wasn't too shabby either, NOT to mention the various geographical locations concerning the N. AND even a PASI of 50 percent will be good enough to STILL GET YOU BACK INTO A SPEEDO!!!! Now here is the WALRUS.......what did Butch say during the conference call about what type of people being started on Raptiva in the USA???? What does the ADDITION of topicals AND UVA therapy do to the EFFICACY of Raptiva??? THAT's the way UH-HUH, UH-HUH I LIKE IT, UH-HUH UN-HUH!!!!!! RAPTIVA, THE LIGHT TOUCH!!!! Only ONE jab a week will do ya!!!!! A LITTLE jab will do ya!!!!!!! You don't need NO STINKING ENBREL!!!!!!! A LITTLE JAB WILL DO YA!!!!!! So SORRY, Ed, I don't discuss my TRADING tactics in such a HIGH RISK entity such as XOMA. YOU CAN LOSE ALL YOUR MONEY IN RISKY ENTITIES LIKE XOMA!!!!!! It is best left up to INSTITUTIONAL investors in my opinion especially Biotechs in early stages.>>>>>>>>CLEAR is also the first prospective study with a biological treatment in patients whose psoriasis cannot be controlled by, are intolerant to or are contraindicated to other currently available systemic therapies. The results in this sub-group of 526 patients are also consistent with the results in the broader moderate-to-severe population.
